Dopavision Closes €12 Million Series A Round to Advance globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
AMP advice transformation director departs
AMP advice transformation director departs
The director of AMP’s advice transformation program has left the role as the company continues to work towards its three-year turnaround strategy.
A
A
“I can confirm that Ms Hopkins is no longer with the business. This is a project management role for which we will go through the process to find a suitable replacement,” the spokesperson said.
Ms Hopkins had held a number of senior business roles prior to her stint at AMP and spent five years at CBA as the program director for its Future Advice Model, which sought to deliver a “customer centric and efficient” advice service.
Print
AMP advice transformation program director, Jill Hopkins, has departed the company and the company will go through the process of finding a replacement.
Money Management understands that Hopkins had reached her six-month probation on a 12-month contract and the company chose not to retain her.
Hopkins joined the company in November 2020, and had spent five years at CBA as program director of the Future Advice Model and CFP Supervision and Monitoring programs.
Related News:
Novartis Pharma AG: Novartis Phase III Beovu data show potential for fluid resolution in more diabetic macular edema patients with fewer injections versus aflibercept
1
More patients treated with Beovu 6 mg experienced fluid (IRF/SRF) resolution at week 32 and week 52 versus aflibercept; fluid is a key marker of disease activity in DME
1
1
Phase III KESTREL and KITE trials are the first pivotal trials to assess an anti-VEGF on six-week dosing intervals in the loading phase, suggesting Beovu may offer fewer injections from the start of treatment
1
Novartis is committed to bringing Beovu 6 mg to DME patients and will submit data from KESTREL and KITE to global health authorities in H1 2021